Perspective Therapeutics, Inc. (NYSE:CATX) CEO Johan M. Spoor Acquires 100,000 Shares

Perspective Therapeutics, Inc. (NYSE:CATXGet Free Report) CEO Johan M. Spoor purchased 100,000 shares of the company’s stock in a transaction dated Thursday, June 13th. The stock was acquired at an average price of $1.17 per share, with a total value of $117,000.00. Following the completion of the transaction, the chief executive officer now owns 137,572 shares of the company’s stock, valued at approximately $160,959.24. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Perspective Therapeutics Trading Down 7.8 %

Shares of NYSE:CATX opened at $1.07 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 12.98 and a quick ratio of 12.98. Perspective Therapeutics, Inc. has a 1 year low of $0.21 and a 1 year high of $1.91.

Perspective Therapeutics’s stock is scheduled to reverse split before the market opens on Monday, June 17th. The 1-10 reverse split was announced on Monday, June 17th. The number of shares owned by shareholders will be adjusted after the market closes on Monday, June 17th.

Perspective Therapeutics (NYSE:CATXGet Free Report) last posted its earnings results on Wednesday, May 15th. The company reported ($0.02) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.01. The firm had revenue of $0.33 million for the quarter. Perspective Therapeutics had a negative net margin of 302.70% and a negative return on equity of 46.38%. As a group, sell-side analysts expect that Perspective Therapeutics, Inc. will post -0.11 EPS for the current fiscal year.

Institutional Trading of Perspective Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of CATX. Bank of New York Mellon Corp bought a new stake in shares of Perspective Therapeutics during the third quarter worth $42,000. HighTower Advisors LLC bought a new stake in shares of Perspective Therapeutics in the third quarter worth $314,000. Taylor & Morgan Wealth Management LLC grew its stake in shares of Perspective Therapeutics by 8.7% in the fourth quarter. Taylor & Morgan Wealth Management LLC now owns 625,000 shares of the company’s stock worth $251,000 after purchasing an additional 50,000 shares during the last quarter. Simplicity Wealth LLC bought a new stake in shares of Perspective Therapeutics in the first quarter worth $40,000. Finally, ZWJ Investment Counsel Inc. bought a new stake in shares of Perspective Therapeutics in the first quarter worth $26,000. Institutional investors own 54.66% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the stock. Oppenheimer reiterated an “outperform” rating and issued a $1.50 price target (up from $1.20) on shares of Perspective Therapeutics in a research report on Monday, April 1st. Royal Bank of Canada reiterated an “outperform” rating and issued a $3.00 price target on shares of Perspective Therapeutics in a research report on Friday. Lifesci Capital reiterated an “outperform” rating on shares of Perspective Therapeutics in a research report on Monday, May 6th. B. Riley lifted their price objective on shares of Perspective Therapeutics from $1.20 to $1.70 and gave the company a “buy” rating in a research note on Tuesday, April 9th. Finally, Cantor Fitzgerald assumed coverage on shares of Perspective Therapeutics in a research note on Thursday, May 9th. They issued an “overweight” rating on the stock. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $1.90.

Get Our Latest Stock Analysis on Perspective Therapeutics

About Perspective Therapeutics

(Get Free Report)

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.

Featured Stories

Insider Buying and Selling by Quarter for Perspective Therapeutics (NYSE:CATX)

Receive News & Ratings for Perspective Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perspective Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.